Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4070 - Crizotinib vs Platinum-based Chemotherapy as First-line Treatment for Advanced Non-small Cell Lung Cancer with Different ROS1 Fusion Variants

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Haiyan Xu

Citation

Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260

Authors

H. Xu1, Q. Zhang2, L. Liang3, J. Li4, Z. Liu5, G. Yang6, L. Yang4, J. Ying7, S. Zhang8, Y. Wang9

Author affiliations

  • 1 Department Of Comprehensive Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100021 - Beijing/CN
  • 2 Department Of Medical Oncology, Beijing Chest Hospital, 101149 - Beijing/CN
  • 3 Department Of Medical Oncology, Peking University Third Hospital, 100191 - Beijing/CN
  • 4 Department Of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100021 - Beijing/CN
  • 5 Department Of Medical Oncology, Chinese PLA General Hospital, 100039 - Beijing/CN
  • 6 Department Of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100021 - Beiijing/CN
  • 7 Department Of Pathology, Cancer Hospital ,Chinese Academy of Medical Sciences&Peking Union Medical College, 100021 - Beijing/CN
  • 8 Department Of Medical Oncology, Beijing Chest Hospital, Capital Medical University,, Beijing/CN
  • 9 Department Of Medical Oncology, Cancer Hospital ,Chinese Academy of Medical Sciences&Peking Union Medical College, 100021 - Beijing/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4070

Background

ROS1 rearrangement, a novel specific molecular subtype of non-small cell lung cancer (NSCLC), has become a validated therapeutic target. However, the efficacy of crizotinib and platinum-based chemotherapy as first-line treatment between different ROS1 fusion variants in advanced Chinese NSCLC patients has not yet been fully elucidated. This study explored which treatment regimen would be better in such patients.

Methods

Retrospective real-world analyses of clinical and treatment outcome with ROS1-positive advanced NSCLC patients from multi-center study were explored in China, from Jan 9th 2011 to Jan 1st 2019. The study evaluated first-line regimens including crizotinib treatment and platinum-based chemotherapy. The primary endpoint was progression-free survival (PFS), and second endpoints were the objective response rate (ORR) and overall survival (OS). Kaplan-Meier survival analysis was carried out by using SPSS 16.0.

Results

A total of 102 patients, 75 (73.5%) females and 27 (26.5%) males were enrolled. The median age of patients was 52 years and 99 (97.1%) were identified with adenocarcinoma type. 57 cases were administered crizotinib and 45 received platinum-based chemotherapy. For the first-line treatment, the median PFS was significantly longer for crizotinib treatment compared with platinum-based chemotherapy (median,15.0 vs. 9.7months, p = 0.006), respectively. 58 cases were confirmed ROS1 fusion variants by next-generation sequence (NGS) including CD74 fusion (n = 32) and non-CD74 fusion(n = 26). Patients receiving crizotinib with the CD74 fusion had a significant longer PFS than those by platinum-based chemotherapy (median,18.3 vs. 8.8months, p = 0.002); in contrast, a statistical significance was not observed on PFS in the non-CD74 fusion subgroup (12.2 vs. 9.0 months, p = 0.544). The ORR of crizotinib treatment was higher than that of platinum-based chemotherapy (80.7% vs. 55.6%, p = 0.006). OS was not reached owing to immature data.

Conclusions

Crizotinib as first-line treatment tends to have more benefit than platinum-based chemotherapy for advanced Chinese NSCLC patients with CD74 ROS1 fusion variant.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.